Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
Authors:
Open Access
- 1 December 2019
- journal article
- editorial
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 8 (Suppl 6) , S585-S588
Abstract
Avelumab plus axitinib vs . sunitinib for advanced renal-cell carcinomaKeywords
This publication has 19 references indexed in Scilit:
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialThe Lancet Oncology, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Cancer‐specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989‐2005)Cancer, 2008
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003